 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...3637383940414243444546...4748» |
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Tagrisso (osimertinib) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance (clinicaltrials.gov) - Mar 19, 2020
P2, N=60, Not yet recruiting, Sponsor: Guangzhou Institute of Respiratory Disease
- | Imfinzi (durvalumab) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy: Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study (clinicaltrials.gov) - Mar 18, 2020
P2, N=33, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy: Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study (clinicaltrials.gov) - Mar 18, 2020
P2, N=33, Not yet recruiting, Sponsor: Xiaorong Dong
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 17, 2020
P2, N=48, Recruiting, Sponsor: Sun Yat-sen University
Trial primary completion date: Dec 2019 --> Sep 2020
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial initiation date, Metastases: Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma (clinicaltrials.gov) - Mar 17, 2020
P2, N=70, Not yet recruiting, Sponsor: Sun Yat-sen University
Trial primary completion date: Dec 2019 --> Sep 2020 Initiation date: Nov 2019 --> Apr 2020
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: AHNATHY: Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer (clinicaltrials.gov) - Mar 16, 2020
P2, N=12, Recruiting, Sponsor: Fudan University
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Anlotinib Attenuates Pulmonary Fibrosis by Inhibiting Glycolytic Reprogramming (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area E) - Mar 15, 2020 - Abstract #ATS2020ATS_7460;
Our results demonstrate that the anti-fibrotic effect of anlotinib is considered to be associated with the inhibition of glycolytic reprogramming. Since anlotinib has both preventive and therapeutic effects on pulmonary fibrosis, anlotinib has potential as a novel therapeutic treatment for IPF.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy, Metastases: SAGC: Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Mar 9, 2020
P2, N=80, Recruiting, Sponsor: Zhejiang Cancer Hospital
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] COST-EFFECTIVENESS ANALYSIS OF ANLOTINIB AS A THIRD-LINE OR FURTHER TREATMENT IN ADVANCED NON-SMALL LUNG CANCER () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_479;
The most influential factors of the model were utility of PFS state and the cost of anlotinib. CONCLUSIONS : Anlotinib is not a cost-effective regimen as the third-line and later treatment for the patients with advanced non-small cell lung cancer from the Chinese societal perspective.
- | Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Journal: Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. (Pubmed Central) - Mar 7, 2020
CONCLUSIONS : Anlotinib is not a cost-effective regimen as the third-line and later treatment for the patients with advanced non-small cell lung cancer from the Chinese societal perspective. No abstract available
- | Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Preclinical, Journal: Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer. (Pubmed Central) - Mar 7, 2020
No abstract available No abstract available
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, Journal, Adverse events: Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. (Pubmed Central) - Mar 5, 2020
No abstract available Anlotinb-related adverse events could be controlled by patient education, prophylactic measures, early and active intervention, and dose modification.
- | Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Journal: Antitumor effects of anlotinib in thyroid cancer. (Pubmed Central) - Mar 4, 2020
Moreover, anlotinib suppresses the migration of thyroid cancer cells in vitro and the growth of xenograft thyroid tumors in mice. Our data demonstrate that anlotinib has significant anti-cancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial completion date, Trial primary completion date, Surgery: Rvision-001: Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC (clinicaltrials.gov) - Mar 4, 2020
P2, N=50, Recruiting, Sponsor: Peking University Third Hospital
Our data demonstrate that anlotinib has significant anti-cancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type. Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Mismatch repair, Metastases: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor (clinicaltrials.gov) - Mar 2, 2020
P2, N=138, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- || Avastin (bevacizumab) / Roche
Review, Journal, Combination therapy, IO Biomarker: New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. (Pubmed Central) - Mar 2, 2020
Antiangiogenic agents can achieve therapeutic benefit in advanced NSCLC patients and the combination of chemotherapy, targeted therapy or immunotherapy can lead to synergistic effect. However, exploring the best combination therapy and efficacy-related biomarkers needs further study.
- || Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, Journal: Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma. (Pubmed Central) - Mar 1, 2020
The combination therapy was generally well tolerated. Our study suggests that chemotherapy combined with anlotinib plus anlotinib maintenance therapy had good efficacy and resulted in more favorable survival with good tolerance among patients with advanced/metastatic STS.
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study. (Poster Board 232) - Feb 27, 2020 - Abstract #ASCO2020ASCO_625;
And we will report more results ahout anlotinib in the future. Research Funding: Chia-Tai Tianqing Pharmaceutical Group Co Ltd
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase Ⅱ trial. (Poster Board 205) - Feb 27, 2020 - Abstract #ASCO2020ASCO_596;
Anlotinib showed a promising activity with an acceptable safety profile for patients with recurrent advanced cervical cancer. Research Funding: Chia-Tai Tianqing Pharmaceutical Group Co Ltd
- penpulimab (AK105) / Akesobio, Sino Biopharmaceutical, Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC). (Poster Board 200) - Feb 27, 2020 - Abstract #ASCO2020ASCO_478;
P2
No unexpected AEs were identified beyond the established safety profile for each agent. Evaluation of penpulimab + anlotinib (10 mg QD) in a phase 3 study for 1L HCC is currently underway.
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup analysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC). (Poster Board 188) - Feb 27, 2020 - Abstract #ASCO2020ASCO_81;
P2/3
Treatment with anlotinib exhibited greater PFS benefits for pts with better functional status (ECOG PS = 0), younger age or lower tumor burden. These results indicated that it is reasonable to start anlotinib treatment at a relative earlier disease stage before the worsen of ECOG PS, increase of tumor size or ageing.
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
[VIRTUAL] Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An analysis based on the ALTER01031 trial. (Poster Board 187) - Feb 27, 2020 - Abstract #ASCO2020ASCO_80;
P2/3
Lower baseline Ct level does not mean better prognosis while a rapid Ct decrease may predict improved survival and treatment response to MTC pts received anlotinib. Research Funding: None
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial, Metastases: Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer (clinicaltrials.gov) - Feb 27, 2020
P1/2, N=52, Not yet recruiting, Sponsor: China Medical University, China
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE) (clinicaltrials.gov) - Feb 19, 2020
P2, N=30, Recruiting, Sponsor: Shanghai Changzheng Hospital
- || AL-034 / J&J
New P1/2 trial, Metastases: TQA3334-?-02: A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (clinicaltrials.gov) - Feb 17, 2020
P1/2, N=40, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) (clinicaltrials.gov) - Feb 16, 2020
P2, N=30, Recruiting, Sponsor: Shanghai Changzheng Hospital
- Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical, docetaxel / Generic mfg.
Anlotinib combination with docetaxol for patients with advanced refractory non-small-sell lung cancer: a phase 2, single-arm trial (Hall 1) - Feb 15, 2020 - Abstract #ELCC2020ELCC_419;
- erlotinib / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Erlotinib plus Anlotinib as first-line therapy in patients with advanced non-small-cell lung cancer harboring EGFR mutations (19DEL or L858R): an open-label, phase 2 study (Hall 1) - Feb 15, 2020 - Abstract #ELCC2020ELCC_408;
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Sintilimab in combination with anlotinib as first-line therapy for advanced non-small cell lung cancer (NSCLC): final analysis of primary endpoints (Hall 1) - Feb 15, 2020 - Abstract #ELCC2020ELCC_405;
- | Tyvyt (sintilimab) / Eli Lilly, AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Combination therapy, Metastases: CO-STAR: Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer (clinicaltrials.gov) - Feb 13, 2020
P2, N=30, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- || Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, Retrospective data, Journal: Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib. (Pubmed Central) - Feb 8, 2020
Research Funding: None In 73 extensive-stage SCLC patients treated with anlotinib, no demographic/clinical characteristic was related to tumor cavitation, and tumor cavitation was an independent factor in predicting better PFS.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Metastases: ALTER-C002: Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients (clinicaltrials.gov) - Feb 7, 2020
P2, N=30, Recruiting, Sponsor: Zhejiang University
In 73 extensive-stage SCLC patients treated with anlotinib, no demographic/clinical characteristic was related to tumor cavitation, and tumor cavitation was an independent factor in predicting better PFS. Not yet recruiting --> Recruiting
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion, Trial primary completion date, Metastases: APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) - Feb 6, 2020
P2, N=43, Completed, Sponsor: Peking University People's Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2019 --> Oct 2019
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Combination therapy: Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer (clinicaltrials.gov) - Feb 6, 2020
P2, N=30, Not yet recruiting, Sponsor: Beijing Friendship Hospital
- || Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P1/2 trial: ACTION: A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer (clinicaltrials.gov) - Jan 22, 2020
P1/2, N=30, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P3 trial: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701) (clinicaltrials.gov) - Jan 21, 2020
P3, N=738, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Anlotinib Treatment in Steroid Depenent/Refractory cGVHD (clinicaltrials.gov) - Jan 18, 2020
P2, N=40, Not yet recruiting, Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- || Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, Journal: Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report. (Pubmed Central) - Jan 16, 2020
Some cases of ICC may be responsive to the antiangiogenic drug, anlotinib, when combined with microwave ablation. Randomized clinical studies are required to further confirm the efficacy and safety of anlotinib in the clinical treatment of ICC.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
New P2 trial, Metastases: Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 15, 2020
P2, N=164, Not yet recruiting, Sponsor: Henan Cancer Hospital
- || Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, Review, Journal: Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. (Pubmed Central) - Jan 11, 2020
The tolerability profile of anlotinib is similar to that of other tyrosine kinase inhibitors that target VEGFR and other tyrosine kinase-mediated pathways; however, anlotinib has a significantly lower incidence of grade 3 or higher side effects compared to that of sunitinib. We review the rationale, clinical evidence, and future perspectives of anlotinib for the treatment of multiple cancers.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P4 trial: Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule (clinicaltrials.gov) - Jan 8, 2020
P4, N=70, Recruiting, Sponsor: Henan Cancer Hospital
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial completion date, Trial primary completion date, Metastases: ALTER-L018: Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer (clinicaltrials.gov) - Jan 6, 2020
P2, N=84, Recruiting, Sponsor: Hunan Cancer Hospital
We review the rationale, clinical evidence, and future perspectives of anlotinib for the treatment of multiple cancers. Not yet recruiting --> Recruiting | Trial completion date: Oct 2020 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Jun 2020
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Metastases: DRAGON - IV: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer (clinicaltrials.gov) - Jan 6, 2020
P2/3, N=258, Recruiting, Sponsor: Ruijin Hospital
Not yet recruiting --> Recruiting | Trial completion date: Oct 2020 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Jun 2020 Not yet recruiting --> Recruiting
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: A Study of Anlotinib in Subjects With Advanced Malignancy (clinicaltrials.gov) - Jan 2, 2020
P2, N=93, Completed, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- || Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
PK/PD data, Preclinical, Journal: Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study. (Pubmed Central) - Dec 31, 2019
Also, the intra- and interday precisions were both below 15%. This robust method was successfully applied to support the pharmacokinetic study of anlotinib in rats.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Surgery, Metastases, Post-surgery: ALTER-H-004: Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (clinicaltrials.gov) - Dec 29, 2019
P2, N=48, Not yet recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
- | Opdivo (nivolumab) / BMS, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 25, 2019
P2, N=70, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New P2/3 trial, Metastases: DRAGON - IV: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer (clinicaltrials.gov) - Dec 22, 2019
P2/3, N=258, Not yet recruiting, Sponsor: Ruijin Hospital
- |||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: ALTN-AK105-II-02: A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors (clinicaltrials.gov) - Dec 19, 2019
P2, N=140, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Zykadia (ceritinib) / Novartis, Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical, Imbruvica (ibrutinib) / AbbVie, J&J
PK/PD data, Preclinical, Journal: A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study. (Pubmed Central) - Dec 19, 2019
ANL, CER and IBR were sufficiently stable under most investigated conditions. The optimized method was successfully applied for a pharmacokinetic study after single oral gavage administration of mixture (ANL, CER and IBR) at dose of 6 mg kg-1, 25 mg kg-1 and 10 mg kg-1.